Publications by authors named "V Codullo"
Objective: Bosentan (BOS) is approved for treating pulmonary arterial hypertension (PAH) and preventing digital ulcers (DU) in systemic sclerosis (SSc). Our study aimed to evaluate whether BOS prescribed for DU could reduce the incidence of PAH in a large SSc cohort from the SPRING registry.
Methods: Patients with SSc from the SPRING registry, meeting ACR/EULAR 2013 classification criteria with data on PAH onset, DU status, BOS exposure, and at least a one-year follow-up between 2015 and 2020, and no known PAH at baseline were included.
Objective: To optimise the organisation of care and encourage the adoption of good clinical practices, the RarERN Path methodology was designed within ERN ReCONNET. The aim of our work was to report the application of RarERN Path on systemic sclerosis within the ERN ReCONNET centres, providing a feasible and flexible organisational reference model for optimising the systemic sclerosis care pathway in different countries.
Methods: RarERN Path is a six-phase methodology which enables the creation of a reference organisational model co-designed on the basis of the expertise of different stakeholders.
Article Synopsis
- Lung transplantation (LuTx) is a crucial treatment for patients with systemic sclerosis (SSc) and severe lung disease, aiming to improve survival and overall health outcomes.
- A study of 13 SSc patients who underwent LuTx showed significant improvements in lung function, skin involvement, and overall disease activity over a two-year period.
- The survival rate at two years post-transplant was 92.3%, indicating LuTx is a promising option for SSc patients in advanced stages of the disease, with no unexpected adverse events reported.